Osimertinib
Brand name: Tagrisso
Osimertinib comes in 4 pill versions in our database, in 2 strengths, from 2 manufacturers. Check the imprint to tell them apart.
Osimertinib pill images
40 mg 2 pills
- AZ 40 Osimertinib 40 mg Brown, round, 9 mm Used for lung cancer
- AZ 40 Osimertinib Mesylate 40 mg Brown, round Used for lung cancer
80 mg 2 pills
What is Osimertinib used for?
Osimertinib is used for lung cancer.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
Adjuvant Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC
TAGRISSO is indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
First-line Treatment of EGFR Mutation-Positive Metastatic NSCLC
TAGRISSO is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
First-line Treatment of EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC
TAGRISSO in combination with pemetrexed and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC
TAGRISSO is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
From the FDA-approved label on DailyMed (published Sep 25, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.